Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.5K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

217
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
217
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

77
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
77
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

195
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
195
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Type 2 Biomarkers And Their Clinical Implications In Bronchiectasis: A Prospective Cohort Study

Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort Study

Yen-Fu Chen1,2,3, Hsin-Han Hou4, Ning Chien5

  • 1Department of Internal Medicine, National Taiwan University Hospital, Yunlin Branch, Yunlin County, Taiwan.

Lung
|June 17, 2024

Related Experiment Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.6K
Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function
02:09

Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function

Published on: April 12, 2024

577
Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
05:18

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

277

View abstract on PubMed

Summary
This summary is machine-generated.

Type 2 biomarkers like blood eosinophil count and FeNO offer insights into bronchiectasis severity. However, Pseudomonas aeruginosa and neutrophil-to-lymphocyte ratio are stronger predictors of exacerbations.

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Clinical Immunology
  • Biomarker Research

Background:

  • Bronchiectasis is characterized by neutrophilic inflammation, but the role of type 2 biomarkers in disease severity and exacerbation risk remains unclear.
  • Understanding these biomarkers is crucial for improving patient management strategies in bronchiectasis.

Purpose of the Study:

  • To investigate the clinical significance of type 2 biomarkers, including blood eosinophil count (BEC), serum total immunoglobulin E (IgE), and fractional exhaled nitric oxide (FeNO), in patients with bronchiectasis.
  • To assess the association of these biomarkers with disease severity and exacerbation risk.

Main Methods:

  • A cross-sectional cohort study was conducted on 130 bronchiectasis patients (excluding asthma or allergic bronchopulmonary aspergillosis).
  • Clinical and radiological evaluations were performed, alongside bronchoalveolar lavage analysis for cytokines and microbiology.
Keywords:
Pseudomonas aeruginosaBlood eosinophil countBronchiectasisFractional exhaled nitric oxide

Related Experiment Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.6K
Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function
02:09

Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function

Published on: April 12, 2024

577
Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
05:18

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

277
  • Type 2 biomarkers (BEC, serum total IgE, FeNO) were measured during stable disease states, with positive thresholds defined by established criteria.

    • Main Results:

    • Approximately 60% of patients had at least one positive type 2 biomarker (BEC ≥300 cells/μL, FeNO ≥25 ppb, or IgE ≥75 kU/L).
    • BEC and FeNO showed variable impacts on clinical characteristics and disease severity, reflecting different aspects of the disease.
    • Pseudomonas aeruginosa colonization and a high neutrophil-to-lymphocyte ratio (NLR ≥3.0) were more significant predictors of exacerbation frequency than type 2 biomarkers.

    Conclusions:

    • Type 2 biomarkers, particularly BEC and FeNO, play distinct roles in assessing bronchiectasis severity and predicting exacerbation risk.
    • A multi-biomarker strategy, integrating type 2 biomarkers with microbiological and clinical assessments, is recommended for comprehensive bronchiectasis management.
    Immunoglobulin E
    Type 2 biomarkers